Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q18PE1
UPID:
DOK7_HUMAN
Alternative names:
Downstream of tyrosine kinase 7
Alternative UPACC:
Q18PE1; A2A499; A2RRD4; E9PB56; Q6P6A6; Q86XG5; Q8N2J3; Q8NBC1
Background:
Protein Dok-7, also known as Downstream of tyrosine kinase 7, plays a pivotal role in neuromuscular synaptogenesis. It acts as a muscle-intrinsic activator of MUSK, essential for acetylcholine receptor clustering and neuromuscular junction formation.
Therapeutic significance:
Dok-7 is linked to congenital myasthenic syndrome 10 and fetal akinesia deformation sequence 3, diseases affecting neuromuscular transmission and fetal movement. Targeting Dok-7 pathways could offer new treatments for these disorders.